PCM
AKBA icon

Piermont Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Piermont Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10,830
Closed -$103K – 236
2018
Q1 		$103K Sell
10,830
-1,670
-13% -$23.4K 0.03% 237
2017
Q4 		$186K Sell
12,500
-15,270
-55% -$253K 0.06% 232
2017
Q3 		$546K Sell
27,770
-27,305
-50% -$420K 0.18% 146
2017
Q2 		$791K Sell
55,075
-9,580
-15% -$121K 0.23% 186
2017
Q1 		$595K Buy
+64,655
New +$631K 0.14% 215

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Piermont Capital Management's AKBA Position: Q2 2018 in Review

Piermont Capital Management sold out of Akebia Therapeutics (AKBA) in Q2 2018, closing a stake of 10,830 shares — an estimated $103K sold.

Piermont Capital Management first reported a position in AKBA in Q1 2017 and held it in 5 quarters. The position peaked at $791K in Q2 2017. 145 funds tracked by Wall St. Rank hold AKBA as of Q2 2018.

  • Piermont Capital Management reported no remaining Akebia Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Piermont Capital Management sold 10,830 Akebia Therapeutics shares in Q2 2018, an estimated $103K.
  • Piermont Capital Management first reported a position in Akebia Therapeutics in Q1 2017 and held it in 5 quarters.
  • Piermont Capital Management's Akebia Therapeutics position peaked at $791K in Q2 2017.
  • 145 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2018.

Based on Piermont Capital Management's 13F filing for Q2 2018, filed 10 Aug 2018.